None listed
Conditions
Interventions
Drug : The patients with pathologic T2-3 or N1 esophageal squamous cell carcinoma will be enrolled by informed consent, after 3-8weeks since curative resection of esophageal cancer. After stratified r
s opinion. For both groups, regular follow-up by chest-CT will be performed every 6months until 5 years since treatment.
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients must have histologically or cytologically documented esophageal cancer (squamous cell carcinoma) including esoophgeal squamous cell cancer of the esophagogastric junction 2) Patients who underwent curative surgical resection for esophageal ca (postop. 3-8 wks) 3) T 2-3 or N1 4) Age: 18-70 5) ECOG performance status: 0-2 6) No previous history of chemotherapy or radiation therapy 7) Adequate bone marrow, liver, kidney function 8) Signed written informed consent
Exclusion criteria
Exclusion criteria: 1) Cervical esophageal cancer 2) Subject who received neoadjuvant chemotherapy, biologic therapy or radiation therapy 3) Evidence of brain metastasis 4) Concurrent serious medical or major psychiatric illness 5) Active or uncontrolled infection 6) Pregnant or lactating woman 7) Gastroesophageal junction involvement of stomach cancer 8) Synchronous or metachronous double primary cancer 9) History of other malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;pattern of failure;toxicity profile;predictive markers | — |
Countries
Korea, Republic of
Contacts
Public ContactGenehee Lee
Samsung Medical Center
Outcome results
None listed